These p40-expressing CAR T cells not only had a better safety profile but also displayed better efficacy against neuroblastoma and pancreatic cancer CDXs by promoting antigen-dependent proliferation and CAR T-cell persistence compared to IL-15 or IL-18. Here, IL18 is linked to pancreatic neoplasm.